ATE178907T1 - Rezeptorbindende region des diphtherietoxius - Google Patents

Rezeptorbindende region des diphtherietoxius

Info

Publication number
ATE178907T1
ATE178907T1 AT93911012T AT93911012T ATE178907T1 AT E178907 T1 ATE178907 T1 AT E178907T1 AT 93911012 T AT93911012 T AT 93911012T AT 93911012 T AT93911012 T AT 93911012T AT E178907 T1 ATE178907 T1 AT E178907T1
Authority
AT
Austria
Prior art keywords
receptor
toxius
diphtherial
binding region
diphtheria toxin
Prior art date
Application number
AT93911012T
Other languages
English (en)
Inventor
R John Collier
David Eisenberg
Haian Fu
Seunghyon Choe
Original Assignee
Harvard College
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harvard College, Univ California filed Critical Harvard College
Application granted granted Critical
Publication of ATE178907T1 publication Critical patent/ATE178907T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/34—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Corynebacterium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Public Health (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Photoreceptors In Electrophotography (AREA)
  • Electronic Switches (AREA)
  • Superconductors And Manufacturing Methods Therefor (AREA)
AT93911012T 1992-05-06 1993-05-03 Rezeptorbindende region des diphtherietoxius ATE178907T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US88139492A 1992-05-06 1992-05-06

Publications (1)

Publication Number Publication Date
ATE178907T1 true ATE178907T1 (de) 1999-04-15

Family

ID=25378382

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93911012T ATE178907T1 (de) 1992-05-06 1993-05-03 Rezeptorbindende region des diphtherietoxius

Country Status (10)

Country Link
US (1) US5843711A (de)
EP (1) EP0643559B1 (de)
JP (1) JP3506431B2 (de)
AT (1) ATE178907T1 (de)
AU (1) AU4230493A (de)
CA (1) CA2135052A1 (de)
DE (1) DE69324487T2 (de)
ES (1) ES2130265T3 (de)
GR (1) GR3030141T3 (de)
WO (1) WO1993021769A1 (de)

Families Citing this family (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6455673B1 (en) * 1994-06-08 2002-09-24 President And Fellows Of Harvard College Multi-mutant diphtheria toxin vaccines
US5917017A (en) * 1994-06-08 1999-06-29 President And Fellows Of Harvard College Diphtheria toxin vaccines bearing a mutated R domain
US5843462A (en) * 1995-11-30 1998-12-01 Regents Of The University Of Minnesota Diphtheria toxin epitopes
HU227893B1 (en) 2000-06-29 2012-05-29 Glaxosmithkline Biolog Sa Vaccine compositions
GB0108364D0 (en) 2001-04-03 2001-05-23 Glaxosmithkline Biolog Sa Vaccine composition
AU2004208962B2 (en) 2003-02-10 2010-07-15 To-Bbb Holding B.V. Differentially expressed nucleic acids in the blood-brain barrier under inflammatory conditions
EP1947116B1 (de) * 2003-02-10 2017-06-21 2-BBB Medicines B.V. Differenziell exprimierte Nukleinsäuren der Blut-Hirnschranke bei einer Entzündung
DE602004028262D1 (de) 2003-10-02 2010-09-02 Glaxosmithkline Biolog Sa B. pertussis antigene und ihre verwendung bei der vakzinierung
EP1687016A4 (de) * 2003-11-25 2009-07-29 Anjin Corp Diphertie-toxin-variante
GB0505996D0 (en) 2005-03-23 2005-04-27 Glaxosmithkline Biolog Sa Fermentation process
US7179159B2 (en) * 2005-05-02 2007-02-20 Applied Materials, Inc. Materials for chemical mechanical polishing
US8398983B2 (en) 2005-06-27 2013-03-19 Glaxosmithkline Biologicals, S.A. Immunogenic composition
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
PL1973564T3 (pl) 2005-12-22 2017-04-28 Glaxosmithkline Biologicals S.A. Szczepionki zawierające koniugaty polisacharydu otoczkowego streptococcus pneumoniae
US8945582B2 (en) 2006-09-07 2015-02-03 Glaxosmithkline Biologicals S.A. Vaccine
BRPI0810778A2 (pt) 2007-05-02 2011-09-13 Glaxosmithkline Biolog Sa kit, vacina combinada, e, métodos de diminuição da interferência de vizinhança de crm sobre um antìgeno sensìvel em um esquema de imunização primária de uma vacina, e de diminuição da interferência de vizinhança sobre um antìgeno sensìvel, e, uso de conjugados de sacarìdeo
JP2010530895A (ja) * 2007-06-21 2010-09-16 アンジェリカ セラピューティックス，インク． 修飾毒素
SI2167121T1 (sl) 2007-06-26 2015-12-31 Glaxosmithkline Biologicals S.A. Cepivo, ki obsega kapsularne polisaharidne konjugate Streptococcusa pneumoniae
EP2268297A4 (de) * 2008-02-29 2011-11-16 Angelica Therapeutics Inc Modifizierte toxine
EP2349209A2 (de) * 2008-09-26 2011-08-03 Nanobio Corporation Therapeutische zusammensetzungen in nanoemulsionsform und anwendungsverfahren dafür
AU2010243285B2 (en) 2009-04-30 2013-06-06 Coley Pharmaceutical Group, Inc. Pneumococcal vaccine and uses thereof
WO2010132833A1 (en) 2009-05-14 2010-11-18 The Regents Of The University Of Michigan Streptococcus vaccine compositions and methods of using the same
PE20161551A1 (es) * 2009-09-03 2017-01-18 Pfizer Vaccines Llc Vacuna de pcsk9
GB0917647D0 (en) 2009-10-08 2009-11-25 Glaxosmithkline Biolog Sa Expression system
GB201003922D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Conjugation process
AU2011325871B2 (en) 2010-11-05 2016-02-04 Medvet Science Pty Ltd Markers of endothelial progenitor cells and uses thereof
US20140004142A1 (en) 2011-03-02 2014-01-02 Pfizer Inc. Pcsk9 vaccine
GB201103836D0 (en) 2011-03-07 2011-04-20 Glaxosmithkline Biolog Sa Conjugation process
GB201105981D0 (en) 2011-04-08 2011-05-18 Glaxosmithkline Biolog Sa Novel process
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
FR2988393B1 (fr) 2012-03-20 2014-05-09 Commissariat Energie Atomique Inhibiteur de l'hb-egf derive du domaine r de la toxine diphterique pour le traitement des maladies associees a l'activation de la voie hb-egf/egfr
US9764006B2 (en) 2012-12-10 2017-09-19 The General Hospital Corporation Bivalent IL-2 fusion toxins
US9802987B2 (en) 2013-03-08 2017-10-31 Pfizer Inc. Immunogenic fusion polypeptides
AP2015008702A0 (en) 2013-03-08 2015-09-30 Crucell Holland Bv Acellular pertussis vaccine
EP2968450A4 (de) 2013-03-15 2016-10-26 Angelica Therapeutics Inc Modifizierte toxine
RU2662968C2 (ru) 2013-09-08 2018-07-31 Пфайзер Инк. Иммуногенная композиция против neisseria meningitidis (варианты)
WO2015095868A1 (en) 2013-12-20 2015-06-25 Wake Forest University Health Sciences Methods and compositions for increasing protective antibody levels induced by pneumococcal polysaccharide vaccines
BR112016016580B1 (pt) 2014-01-21 2024-01-09 Pfizer Inc Processo para a preparação de um conjugado imunogênico, conjugado imunogênico, composição imunogênica, e vacina
IL312327B2 (en) 2014-01-21 2026-02-01 Pfizer Immunogenic preparations comprising conjugated capsular saccharide antigens and their uses
US11160855B2 (en) 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
CN120718167A (zh) 2014-01-21 2025-09-30 辉瑞大药厂 肺炎链球菌荚膜多糖及其缀合物
EP3104886B1 (de) 2014-02-14 2018-10-17 Pfizer Inc Immunogene glykoproteinkonjugate
CN107427568B (zh) 2015-01-15 2021-12-14 辉瑞公司 用于肺炎球菌疫苗中的免疫原性组合物
CA2990852A1 (en) 2015-06-26 2016-12-29 Beth Israel Deaconess Medical Center, Inc. Cancer therapy targeting tetraspanin 33 (tspan33) in myeloid derived suppressor cells
CN108367063A (zh) 2015-07-21 2018-08-03 辉瑞公司 包含缀合的荚膜糖抗原的免疫原性组合物及其试剂盒和用途
GB201518684D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Vaccine
JP6884145B2 (ja) 2015-11-20 2021-06-09 ファイザー・インク 肺炎連鎖球菌ワクチンにおいて用いるための免疫原性組成物
KR20180088458A (ko) 2015-12-04 2018-08-03 다나-파버 캔서 인스티튜트 인크. 암의 치료를 위한 mica/b 알파 3 도메인의 백신접종
EP3554544A4 (de) 2016-12-16 2020-07-29 Bluefin Biomedicine, Inc. Anti-cub-haltige protein 1-(cdcp1)-antikörper, antikörper-wirkstoff-konjugate und verfahren zur verwendung davon
US11413344B2 (en) 2017-01-20 2022-08-16 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
ES3048958T3 (en) 2017-01-31 2025-12-12 Merck Sharp & Dohme Llc Methods for production of capsular polysaccharide protein conjugates from streptococcus pneumoniae serotype 19f
AU2018215585B2 (en) 2017-01-31 2022-03-17 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
CN110225764A (zh) 2017-01-31 2019-09-10 默沙东公司 制备多糖-蛋白缀合物的方法
WO2018156465A1 (en) * 2017-02-24 2018-08-30 Merck Sharp & Dohme Corp. Polysaccharide-protein conjugates utilizing diphtheria toxin fragment b as a carrier
PT3585803T (pt) 2017-02-24 2025-12-22 Merck Sharp & Dohme Formulações de vacina pneumocócica conjugada
CA3066020A1 (en) 2017-06-16 2018-12-20 Glaxosmithkline Biologicals Sa Method of treatment
GB201711635D0 (en) 2017-07-19 2017-08-30 Glaxosmithkline Biologicals Sa Immunogenic composition
PT3678654T (pt) 2017-09-07 2024-08-05 Merck Sharp & Dohme Llc Polissacáridos pneumocócicos e sua utilização em conjugados imunogénicos de polissacárido-proteína transportadora
TWI725359B (zh) 2017-12-06 2021-04-21 美商默沙東藥廠 包含肺炎鏈球菌多醣-蛋白結合物之組合物及其使用方法
WO2020016322A1 (en) 2018-07-19 2020-01-23 Glaxosmithkline Biologicals Sa Processes for preparing dried polysaccharides
US11260119B2 (en) 2018-08-24 2022-03-01 Pfizer Inc. Escherichia coli compositions and methods thereof
US20220054632A1 (en) 2018-12-12 2022-02-24 Glaxosmithkline Biologicals Sa Modified carrier proteins for o-linked glycosylation
CA3120922A1 (en) 2018-12-12 2020-06-18 Pfizer Inc. Immunogenic multiple hetero-antigen polysaccharide-protein conjugates and uses thereof
GEAP202415690A (en) 2018-12-19 2024-01-10 Merck Sharp & Dohme Llc Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof
CA3129425A1 (en) 2019-02-11 2020-08-20 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
EP3927731A4 (de) 2019-02-19 2022-12-28 The Regents of the University of Colorado, a body corporate Bispezifische immunotoxine zur targeting von menschlichen cd25s-ccr4+ tumoren und regulatorischen t-zellen
JP7239509B6 (ja) 2019-02-22 2023-03-28 ファイザー・インク 細菌多糖類を精製するための方法
CA3136278A1 (en) 2019-04-10 2020-10-15 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
BR112022001654A2 (pt) 2019-07-31 2022-07-12 Sanofi Pasteur Inc Composições conjugadas de proteinas de polissacarídeos pneumocócicos multivalentes e métodos de utilização dos mesmos
EP4034157A1 (de) 2019-09-27 2022-08-03 Pfizer Inc. Neisseria-meningitidis-zusammensetzungen und verfahren dafür
CA3159573A1 (en) 2019-11-01 2021-05-06 Pfizer Inc. Escherichia coli compositions and methods thereof
US12533418B2 (en) 2019-11-22 2026-01-27 Glaxosmithkline Biologicals Sa Dosage and administration of a bacterial saccharide glycoconjugate vaccine
CA3171864A1 (en) 2020-02-21 2021-08-26 Pfizer Inc. Purification of saccharides
NZ790372A (en) 2020-02-23 2026-01-30 Pfizer Escherichia coli compositions and methods thereof
JP2023546446A (ja) 2020-10-22 2023-11-02 ファイザー・インク 細菌多糖を精製する方法
MX2023004912A (es) 2020-10-27 2023-05-16 Pfizer Composiciones de escherichia coli y metodos de las mismas.
US12138302B2 (en) 2020-10-27 2024-11-12 Pfizer Inc. Escherichia coli compositions and methods thereof
KR20230097160A (ko) 2020-11-04 2023-06-30 화이자 인코포레이티드 폐렴구균 백신에 사용하기 위한 면역원성 조성물
US12357681B2 (en) 2020-12-23 2025-07-15 Pfizer Inc. E. coli FimH mutants and uses thereof
TW202245835A (zh) 2021-02-04 2022-12-01 美商默沙東有限責任公司 用於肺炎球菌結合物疫苗之奈米乳化液佐劑組合物
WO2022234416A1 (en) 2021-05-03 2022-11-10 Pfizer Inc. Vaccination against pneumoccocal and covid-19 infections
CA3218544A1 (en) 2021-05-03 2022-11-10 Pfizer Inc. Vaccination against bacterial and betacoronavirus infections
EP4346893A2 (de) 2021-05-28 2024-04-10 Pfizer Inc. Immunogene zusammensetzungen mit konjugierten kapselsaccharidantigenen und verwendungen davon
MX2023013434A (es) 2021-05-28 2023-12-12 Pfizer Composiciones inmunogenas que comprenden antigenos de sacarido capsular conjugados y sus usos.
CA3247998A1 (en) 2022-01-13 2023-07-20 Pfizer Inc. Immunogenic compositions based on conjugated capsular saccharidic antigens and their uses
WO2023161817A1 (en) 2022-02-25 2023-08-31 Pfizer Inc. Methods for incorporating azido groups in bacterial capsular polysaccharides
WO2024084397A1 (en) 2022-10-19 2024-04-25 Pfizer Inc. Vaccination against pneumoccocal and covid-19 infections
WO2024110827A1 (en) 2022-11-21 2024-05-30 Pfizer Inc. Methods for preparing conjugated capsular saccharide antigens and uses thereof
JP2025537898A (ja) 2022-11-22 2025-11-20 ファイザー・インク コンジュゲートさせた莢膜糖類抗原を含む免疫原性組成物およびその使用
IL321069A (en) 2022-12-01 2025-07-01 Pfizer Pneumococcal conjugate vaccine preparations
EP4661911A1 (de) 2023-02-10 2025-12-17 Pfizer Inc. Immunogene zusammensetzungen mit konjugierten kapselsaccharidantigenen und verwendungen davon
KR20250163977A (ko) 2023-03-30 2025-11-21 화이자 인코포레이티드 접합된 피막 사카라이드 항원을 포함하는 면역원성 조성물 및 그의 용도
EP4694921A1 (de) 2023-04-14 2026-02-18 Pfizer Inc. Immunogene zusammensetzungen mit konjugierten kapselsaccharidantigenen und verwendungen davon
EP4701656A1 (de) 2023-04-24 2026-03-04 Pfizer Inc. Immunogene zusammensetzungen mit konjugierten kapselsaccharidantigenen und verwendungen davon
AU2024271872A1 (en) 2023-05-18 2025-12-18 Merck Sharp & Dohme Llc Compounds and adjuvant formulations useful in pneumococcal vaccines
WO2024241172A2 (en) 2023-05-19 2024-11-28 Glaxosmithkline Biologicals Sa Methods for eliciting an immune response to respiratory syncycial virus and streptococcus pneumoniae infection
WO2025057078A1 (en) 2023-09-14 2025-03-20 Pfizer Inc. Adjuvanted immunogenic compositions comprising conjugated pneumococcal capsular saccharide antigens and uses thereof
WO2025106603A1 (en) 2023-11-16 2025-05-22 Merck Sharp & Dohme Llc Peptide conjugate vaccine compositions and methods for the treatment of alzheimer's disease
WO2025133971A1 (en) 2023-12-23 2025-06-26 Pfizer Inc. Improved methods for producing bacterial capsular saccharide glycoconjugates
WO2025186705A2 (en) 2024-03-06 2025-09-12 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
TW202602467A (zh) 2024-03-11 2026-01-16 美商輝瑞股份有限公司 包含經共軛之大腸桿菌糖的免疫原性組成物及其用途
WO2025219908A2 (en) 2024-04-19 2025-10-23 Pfizer Inc. Media and fermentation methods for polysaccharide production in bacterial cell culture
WO2025219904A1 (en) 2024-04-19 2025-10-23 Pfizer Inc. Improved methods for producing glycoconjugates by reductive amination in aprotic solvent

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4709017A (en) * 1985-06-07 1987-11-24 President And Fellows Of Harvard College Modified toxic vaccines
US4950740A (en) * 1987-03-17 1990-08-21 Cetus Corporation Recombinant diphtheria vaccines
IL89504A0 (en) * 1988-03-08 1989-09-10 Univ Wyoming Diphtheria toxin derivative,process for the preparation thereof and pharmaceutical composition containing the same

Also Published As

Publication number Publication date
EP0643559A4 (de) 1997-01-15
EP0643559A1 (de) 1995-03-22
WO1993021769A1 (en) 1993-11-11
DE69324487D1 (de) 1999-05-20
AU4230493A (en) 1993-11-29
JP3506431B2 (ja) 2004-03-15
ES2130265T3 (es) 1999-07-01
EP0643559B1 (de) 1999-04-14
GR3030141T3 (en) 1999-08-31
DE69324487T2 (de) 1999-08-12
US5843711A (en) 1998-12-01
JPH07506821A (ja) 1995-07-27
CA2135052A1 (en) 1993-11-11

Similar Documents

Publication Publication Date Title
ATE178907T1 (de) Rezeptorbindende region des diphtherietoxius
NZ512083A (en) Methods of increasing lean tissue mass using OB protein compositions
DK1266965T3 (da) Rekombinante antistoffer til human terapi
DK0536275T3 (da) Tumorvækstinhibitorer udledt fra væv, fremgangsmåde til deres fremstilling samt anvendelse heraf
PT735818E (pt) Proteinas inflamatorias de macrofagos pim-3 pim-4 e pim-1y
DE68916722D1 (de) Urethan geschützte aminosäuren-n-carboxyanhydride.
DK0853487T3 (da) Neutraliserende monoklonale antistoffer mod respiratorisk syncytial virus
EA199800946A1 (ru) Концентрированный препарат антител
TR199801722T2 (xx) Peptit imm�nojenler.
YU48250B (sh) Postupak za pripremanje aktivne vakcine protiv lajmske bolesti
EP0960936A4 (de) Rekonstituierter menschlicher anti-hm.1 antikörper
ATE267610T1 (de) Glykosylierte igg antikörper
EP0261224A4 (de) Synthetische htlv-iii-peptid-zusammensetzungen und ihre verwendung.
DE68925226D1 (de) Monoklonale Antikörper
NO883306D0 (no) Farmasoeytisk aktive konjugater med forbedret bindingsspesifisitet for kroppsvev.
BR9810907A (pt) Anticorpos monoclonais e policlonais, peptìdeo suscetìvel de gerar um anticorpo, agente imunogênico, sequência de nucleotìdeos, composição farmacêutica, uso de pelo menos um anticorpo, kit de diagnóstico, e, processo para preparar um agente imunogênico
ATE220688T1 (de) Tumor-zerstörende effekte von enterotoxinen und verwandten verbindungen
IT1207589B (it) Composizione di anticorpi monoclonali umani cross-protettivi.
EP0209543A4 (de) Peptidfragmente menschlicher apolipoproteine, typspezifische antikörper und verwendungsverfahren.
DE69010294D1 (de) Verwendung von Antiprogestomimetika zur Stimulierung des Eisprungs.
GB9501826D0 (en) Polypeptide fragments
FI915702A7 (fi) Peptidejä ja niistä johdettuja vasta-aineita HTLV-1 infektion vastaise n rokotuksen määrittämiseksi
DK1039931T3 (da) Multivalente rekombinante antistoffer til at behandle HRV infektioner
DK0513565T3 (da) Monoklonale antistoffer mod plasmin-antiplasmin-komplekset, fremgangsmåde til deres fremstilling og deres anvendelse
FR2646607B1 (fr) Anticorps monoclonaux anti-b2 microglobuline

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee